BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2831 related articles for article (PubMed ID: 7740328)

  • 1. Preclinical evaluation of docetaxel (Taxotere).
    Lavelle F; Bissery MC; Combeau C; Riou JF; Vrignaud P; André S
    Semin Oncol; 1995 Apr; 22(2 Suppl 4):3-16. PubMed ID: 7740328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
    Bissery MC; Vrignaud P; Lavelle F
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
    Bissery MC; Nohynek G; Sanderink GJ; Lavelle F
    Anticancer Drugs; 1995 Jun; 6(3):339-55, 363-8. PubMed ID: 7670132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Taxotere: from yew's needles to clinical practice].
    Lavelle F; Gueritte-Voegelein F; Guenard D
    Bull Cancer; 1993 Apr; 80(4):326-38. PubMed ID: 7909695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Taxoids: structural and experimental properties].
    Lavelle F; Combeau C; Commerçon A
    Bull Cancer; 1995 Apr; 82(4):249-64. PubMed ID: 10846536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel: a review of its pharmacology and clinical activity.
    Trudeau ME
    Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacology of docetaxel.
    Bissery MC
    Eur J Cancer; 1995; 31A Suppl 4():S1-6. PubMed ID: 7577097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future perspectives of docetaxel (Taxotere) in front-line therapy.
    Piccart MJ; Di Leo A
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The scientific rationale for developing taxoids.
    Aapro M
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of docetaxel.
    Eckardt JR
    Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S2-6. PubMed ID: 9435925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
    Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel in breast cancer and a rationale for combination therapy.
    Hortobágyi G
    Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):11-5. PubMed ID: 9213321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
    Bissery MC; Guénard D; Guéritte-Voegelein F; Lavelle F
    Cancer Res; 1991 Sep; 51(18):4845-52. PubMed ID: 1680023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.
    Bissett D; Setanoians A; Cassidy J; Graham MA; Chadwick GA; Wilson P; Auzannet V; Le Bail N; Kaye SB; Kerr DJ
    Cancer Res; 1993 Feb; 53(3):523-7. PubMed ID: 8093854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
    Donnellan PP; Crown JP
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-18-S14-21. PubMed ID: 9335519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxoids: a new class of cytotoxic agents.
    Marty M; Extra JM; Giacchetti S; Cuvier C; Espie M
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S25-8. PubMed ID: 7909941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemical and biological studies on Taxol (Paclitaxel) and Taxotere (Docetaxel), new antineoplastic agents].
    Guéritte-Voegelein F; Guénard D; Dubois J; Wahl A; Potier P
    J Pharm Belg; 1994; 49(3):193-205. PubMed ID: 7914532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel.
    Cortes JE; Pazdur R
    J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 142.